SSRIs and SNRIs in pregnancy

Following a review of epidemiological data, the MHRA has issued advice on the use of SSRIs and SNRIs in pregnancy taking into account the increased risk of persistent pulmonary hypertension in the newborn (PPHN), particularly in later stages of pregnancy.

The advice states that healthcare professionals, including midwives, should be aware of the increased risk of PPHN: the observed increase in risk is about 3 to 4 extra cases per 1000 patients. Enquiry about the use of these medicines, especially in later stages of pregnancy, is encouraged and close observation of neonates exposed to the two classes of agents is recommended after birth.

View MHRA Drug Safety Update

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases